The latest price target for ANI Pharmaceuticals (NASDAQ:ANIP) was reported by Guggenheim on January 16, 2026. The analyst firm set a price target for $124.00 expecting ANIP to rise to within 12 months (a possible 67.09% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for ANI Pharmaceuticals (NASDAQ:ANIP) was provided by Guggenheim, and ANI Pharmaceuticals maintained their buy rating.

There is no last upgrade for ANI Pharmaceuticals

The last downgrade for ANI Pharmaceuticals Inc happened on September 11, 2024 when Truist Securities changed their price target from $80 to $60 for ANI Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ANI Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ANI Pharmaceuticals was filed on January 16, 2026 so you should expect the next rating to be made available sometime around January 16, 2027.

While ratings are subjective and will change, the latest ANI Pharmaceuticals (ANIP) rating was a maintained with a price target of $115.00 to $124.00. The current price ANI Pharmaceuticals (ANIP) is trading at is $74.21, which is out of the analyst’s predicted range.